Gut microbiome clinical trials face challenges like individual variability, strain-specific effects, and stringent regulatory standards. EFSA approval requires precise research questions, robust data, and well-structured experiments. Academic and regulatory expectations conflict, hindering progress. Good science demands rigor, transparency, and collaborative efforts. Effective consumer communication is essential, with alternative research methods proposed to assess health benefits.